Growth Metrics

Sarepta Therapeutics (SRPT) Non-Current Debt (2016 - 2025)

Sarepta Therapeutics has reported Non-Current Debt over the past 16 years, most recently at $829.0 million for Q4 2025.

  • For Q4 2025, Non-Current Debt fell 27.1% year-over-year to $829.0 million; the TTM value through Dec 2025 reached $829.0 million, down 27.1%, while the annual FY2025 figure was $829.0 million, 27.1% down from the prior year.
  • Non-Current Debt for Q4 2025 was $829.0 million at Sarepta Therapeutics, down from $1.0 billion in the prior quarter.
  • Over five years, Non-Current Debt peaked at $1.5 billion in Q4 2022 and troughed at $829.0 million in Q4 2025.
  • A 5-year average of $1.2 billion and a median of $1.1 billion in 2024 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: soared 58.6% in 2021 and later decreased 27.1% in 2025.
  • Year by year, Non-Current Debt stood at $1.1 billion in 2021, then skyrocketed by 40.79% to $1.5 billion in 2022, then dropped by 26.66% to $1.1 billion in 2023, then grew by 0.41% to $1.1 billion in 2024, then dropped by 27.1% to $829.0 million in 2025.
  • Business Quant data shows Non-Current Debt for SRPT at $829.0 million in Q4 2025, $1.0 billion in Q3 2025, and $1.1 billion in Q2 2025.